title: EPA in the prevention of restenosis post PTCA.
abstract: The effect of fish oil on restenosis was evaluated in patients undergoing coronary balloon angioplasty. In addition to routine pharmacotherapy, subjects were given 2.8 g of eicosapentanoic acid (EPA) daily. Treatment was started within twenty-four hours after successful percutaneous transluminal coronary angioplasty (PTCA). After six months of therapy, participants were subjected to coronary arteriography, exercise scintigraphy, exercise electrocardiography, or clinical evaluation. Follow-up evaluation involved 97 coronary lesions in 85 patients. Partial or significant restenosis occurred in 36.5% of patients and 33% of vessels. The presence of severe stenosis before PTCA, dissection, thrombus, multilesion PTCA, and template bleeding time values were not correlated with restenosis. Dilation of the left anterior descending (LAD) and a residual stenosis greater than or equal to 35% were associated with restenosis. Approximately 20% of the patients related difficulty in taking the fish oil. Furthermore, these results show no advantage over expected restenosis rates.
authors.affiliation: Wichita Institute for Clinical Research, Kansas.
authors.forename: M H
authors.initials: MH
authors.lastname: Bowles
authors.forename: D
authors.initials: D
authors.lastname: Klonis
authors.forename: T G
authors.initials: TG
authors.lastname: Plavac
authors.forename: B
authors.initials: B
authors.lastname: Gonzales
authors.forename: D A
authors.initials: DA
authors.lastname: Francisco
authors.forename: R W
authors.initials: RW
authors.lastname: Roberts
authors.forename: G R
authors.initials: GR
authors.lastname: Boxberger
authors.forename: L R
authors.initials: LR
authors.lastname: Poliner
authors.forename: J P
authors.initials: JP
authors.lastname: Galichia
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D003251:Constriction, Pathologic; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control* / Q000628:therapy; D003331:Coronary Vessels / Q000473:pathology; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005080:Exercise Test / Q000187:drug effects; D005500:Follow-Up Studies; D006801:Humans
chemical_list: D000925:Anticoagulants; D015118:Eicosapentaenoic Acid